24131-30-4

Basic information

• Product Name: (3,5-DIMETHOXYBENZYL)TRIPHENYLPHOSPHONIUM BROMIDE
• Synonyms: (3,5-DIMETHOXYBENZYL)TRIPHENYLPHOSPHONIUM BROMIDE
• CAS NO: 24131-30-4
• Molecular Formula: Br*C₂₇H₂₆O₂P
• Molecular Weight: 493.378
• Mol File: 24131-30-4.mol
• Article Data: 29

Chemical Properties

• Melting Point: 275 °C
• Appearance: /
• CAS DataBase Reference: (3,5-DIMETHOXYBENZYL)TRIPHENYLPHOSPHONIUM BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (3,5-DIMETHOXYBENZYL)TRIPHENYLPHOSPHONIUM BROMIDE(24131-30-4)
• EPA Substance Registry System: (3,5-DIMETHOXYBENZYL)TRIPHENYLPHOSPHONIUM BROMIDE(24131-30-4)

Safety Data

• Hazardous Substances Data: 24131-30-4(Hazardous Substances Data)

Usage

Description

(3,5-DIMETHOXYBENZYL)TRIPHENYLPHOSPHONIUM BROMIDE is a quaternary ammonium salt with a phosphonium cation and a bromide anion, known for its role as a phase transfer catalyst in organic synthesis. This chemical compound is recognized for its ability to facilitate the transfer of reactants from an aqueous phase to an organic phase, making it a valuable tool for synthetic chemists due to its stability and ease of handling.

Uses

Used in Organic Synthesis:
(3,5-DIMETHOXYBENZYL)TRIPHENYLPHOSPHONIUM BROMIDE is used as a phase transfer catalyst for facilitating the transfer of reactants from an aqueous phase to an organic phase. This is particularly useful in reactions that involve the formation of carbon-carbon bonds, where it has been shown to be effective across a wide range of reactions.
Used in Carbon-Carbon Bond Formation:
In the field of organic synthesis, (3,5-DIMETHOXYBENZYL)TRIPHENYLPHOSPHONIUM BROMIDE is used as a catalyst to promote the formation of carbon-carbon bonds. Its efficiency in this application aids synthetic chemists in creating complex organic molecules more easily and with greater yields.
Used in Reactions Requiring Phase Transfer Catalysis:
(3,5-DIMETHOXYBENZYL)TRIPHENYLPHOSPHONIUM BROMIDE is used as a phase transfer catalyst in various chemical reactions that require the movement of reactants between different phases. Its effectiveness in these reactions contributes to the advancement of synthetic chemistry and the development of new compounds.

Upstream product

• 2150-37-0 methyl 3,5-dimethoxybenzoate 
• 99-10-5 3,5-Dihydroxybenzoic acid 
• 60732-17-4 2,5-dimethoxybenzyl bromide 
• 603-35-0 triphenylphosphine 
• 7311-34-4 3,5-dimethoxybenzaldehdye 
• 877-88-3 3,5-dimethoxybenzyl bromide 
• 705-76-0 3,5-dimethoxybenzyl alcohol 

Downstream Products

• 20767-18-4 cis-trans-3,3',4',5-tetramethoxystilbene 
• 791115-68-9 cis-3',5'-di-tert-butyl-4'-methoxymethoxy-3,5-dimethoxystilbene 
• 791115-69-0 trans-3',5'-di-tert-butyl-4'-methoxymethoxy-3,5-dimethoxystilbene 
• 871239-45-1 {2-bromo-3-[2-(3,5-dimethoxy-phenyl)-vinyl]-6-methoxy-phenoxy}-tert-butyl-dimethyl-silane 
• 89946-15-6 trans-1-(3,5-dimethoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene 
• 22255-22-7 3,5,4'-trimethoxy-trans-stilbene 
• 94608-23-8 (Z)-1-(3,5-dimethoxyphenyl)-2-(4-methoxyphenyl)ethene 
• 1094739-74-8 1,3-dimethoxy-5-[(Z)-2-(2-allyloxy-4-methoxy-phenyl)-vinyl]-benzene 
• 1094739-73-7 1,3-dimethoxy-5-[(E)-2-(2-allyloxy-4-methoxy-phenyl)-vinyl]-benzene 
• 20578-92-1 2,3′,4,5′-tetramethoxystilbene 

Relevant articles and documents

Synthesis of (E)-2,3′,4,5′-tetramethoxy[2-11C] stilbene

In this paper, we describe the radiosynthesis of the compound (E)-2,3′,4,5′-tetramethoxy[2-11C]stilbene, a potential, universal tumour positron emission tomography imaging agent. The production of (E)-2,3′,4,5′-tetramethoxy[2-11C]sti

FGFR4 INHIBITORS

Methods, compounds, pharmaceutical compositions, and methods of preparing medicaments for treating hepatocellular carcinoma having an altered FGFR4 and/or FGF19 status.

Styrylphenylphthalimides as Novel Transrepression-Selective Liver X Receptor (LXR) Modulators

Anti-inflammatory effects of liver X receptor (LXR) ligands are thought to be largely due to LXR-mediated transrepression, whereas side effects are caused by activation of LXR-responsive gene expression (transactivation). Therefore, selective LXR modulators that preferentially exhibit transrepression activity should exhibit anti-inflammatory properties with fewer side effects. Here, we synthesized a series of styrylphenylphthalimide analogues and evaluated their structure-activity relationships focusing on LXRs-transactivating-agonistic/antagonistic activities and transrepressional activity. Among the compounds examined, 17l showed potent LXR-transrepressional activity with high selectivity over transactivating activity and did not show characteristic side effects of LXR-transactivating agonists in cells. This representative compound, 17l, was confirmed to have LXR-dependent transrepressional activity and to bind directly to LXRβ. Compound 17l should be useful not only as a chemical tool for studying the biological functions of LXRs transrepression but also as a candidate for a safer agent to treat inflammatory diseases.